China’s enthusiasm for OpenClaw is igniting a stock rally in local technology firms moving swiftly to embrace the open-source artificial intelligence program. Tencent Holdings Ltd. shares rose as much as 6.2% Tuesday in Hong Kong after the internet giant launched WorkBuddy, an AI agent for workplace tasks that’s fully compatible with OpenClaw. Knowledge Atlas Technology JSC Ltd. , known as Zhipu, ...
China’s enthusiasm for OpenClaw is igniting a stock rally in local technology firms moving swiftly to embrace the open-source artificial intelligence program. Tencent Holdings Ltd. shares rose as much as 6.2% Tuesday in Hong Kong after the internet giant launched WorkBuddy, an AI agent for workplace tasks that’s fully compatible with OpenClaw. Knowledge Atlas Technology JSC Ltd. , known as Zhipu, surged as much as 16% after launching AutoClaw, a local version of the viral software. MiniMax Group Inc. , which launched its own agent earlier, jumped 15%. OpenClaw is an agent that leverages large language models including Anthropic PBC’s Claude to perform daily functions. Since its launch in November under its original name Clawdbot, the tool has garnered a cult for its ability to operate autonomously to clear user inboxes, make reservations and do other chores. Read more: OpenClaw AI Mania Fires up Chinese Tech Leaders, Cloud Stocks “OpenClaw has created a social media buzz, with companies like Tencent encouraging everyone to install it,” said Shen Meng , director of Beijing-based investment bank Chanson & Co. “It’s a very good opportunity for the local AI model developers to attract users to their existing ecosystems.”
Vitezslav Vylicil/iStock via Getty Images By Ewa Manthey , Commodities Strategist Copper prices have come under pressure in recent weeks as macro headwinds combine with softer physical demand signals. A stronger US dollar, rising energy prices and escalating conflict in the Middle East have triggered a broader risk-off move across financial markets, weighing on sentiment across cyclical assets. At...
Vitezslav Vylicil/iStock via Getty Images By Ewa Manthey , Commodities Strategist Copper prices have come under pressure in recent weeks as macro headwinds combine with softer physical demand signals. A stronger US dollar, rising energy prices and escalating conflict in the Middle East have triggered a broader risk-off move across financial markets, weighing on sentiment across cyclical assets. At the same time, rising exchange inventories, increasing refined output in China and weaker Chinese import demand suggest the tight market that supported prices in recent months may be starting to unwind. Together, these developments suggest the balance in the copper market is beginning to shift. With prices slipping below the $13,000/t level, the following indicators will be key to assessing the near‑term direction for copper. Exchange warehouse inventories Copper inventories are rising rapidly Source: LME, SHFE, COMEX, ING Research Visible copper stocks across major exchanges have risen sharply in recent months. Shanghai Futures Exchange inventories have recently hit a record high as physical demand softened in China, although stocks typically build seasonally around the Lunar New Year holiday. LME inventories, meanwhile, are approaching a 17-month high. The inventory build also reflects strong inflows into LME warehouses, driven by shifting regional pricing incentives. As the COMEX-LME spread narrows, the incentive to redirect metal to the US is fading. As these pricing signals normalise, metal is increasingly being redirected back into LME warehouses and other exchange stocks. With the holiday period now over, the direction of SHFE stocks will be important to watch. A decline in inventories would suggest Chinese demand is holding up at current price levels. Taken together, stocks across the main exchanges have risen by more than 500,000 tonnes since the start of the year, pointing to improving physical availability. The scale of the inventory build suggests supply tightn...
Talks to advance US President Donald Trump’s plan to end the Gaza war have been on hold since last week when the US and Israel jointly attacked Iran, sparking a broader Middle East war, three sources with direct knowledge of the negotiations said. The pause threatens to stall implementation of Trump’s flagship Middle East peace initiative, which he has cast as a major foreign policy objective. It...
Talks to advance US President Donald Trump’s plan to end the Gaza war have been on hold since last week when the US and Israel jointly attacked Iran, sparking a broader Middle East war, three sources with direct knowledge of the negotiations said. The pause threatens to stall implementation of Trump’s flagship Middle East peace initiative, which he has cast as a major foreign policy objective. It comes less than a month after he secured billions of dollars in pledges for Gaza from Gulf Arab states - countries that are now facing Iranian attacks as the conflict widens. Trump’s Gaza plan has hinged in part on whether Hamas militants would lay down their arms in exchange for amnesty, a step intended to pave the way for reconstruction and further Israeli military withdrawals. White House mediators have been backchannelling between Israel and Hamas on the disarmament question. Advertisement Negotiations on this and other issues were paused when the Iran war began on February 28, the three sources said, speaking on condition of anonymity to discuss sensitive talks. A pause in disarmament talks has not been previously reported. 02:22 Trump says US objectives in Iran ‘way ahead of schedule’ and attacks may end ‘soon’ Trump says US objectives in Iran ‘way ahead of schedule’ and attacks may end ‘soon’ A White House official denied there had been any pause in the talks, saying: “Discussions on disarmament are ongoing and positive. All of the mediators agree that this is a critical step to enable rebuilding for the people of Gaza”.
(RTTNews) - Genfit (GNFTF, GNFT.PA) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to NTZ (nitazoxanide), its investigational small-molecule drug candidate. NTZ has been developed as a new formulation for the treatment of Acute-on-Chronic Liver Failure (ACLF), marking an important regulatory milestone for the program. G1090N is GENFIT's lead investigationa...
(RTTNews) - Genfit (GNFTF, GNFT.PA) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to NTZ (nitazoxanide), its investigational small-molecule drug candidate. NTZ has been developed as a new formulation for the treatment of Acute-on-Chronic Liver Failure (ACLF), marking an important regulatory milestone for the program. G1090N is GENFIT's lead investigational program within the ACLF segment of its pipeline. The FDA's ODD recognizes the potential of G1090N's active substance to address this severe, rare condition characterized by rapid deterioration, systemic inflammation, and high short-term mortality. The designation follows recent Phase 1 data demonstrating a favorable safety and tolerability profile in healthy volunteers, as well as compelling anti-inflammatory activity across ex vivo models, providing a solid foundation for advancing the program toward initiation of Phase 2 clinical development, targeted for the second half of 2026. ODD also provides development incentives, including FDA regulatory guidance, certain user fee reductions, and eligibility for seven-year U.S. market exclusivity for the designated indication upon FDA approval. GNFTF closed Monday at $7.87 on the OTC Market, down $2.13 or 21.30%. For More Such Health News, visit rttnews.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.